REGENXBIO reported Q4 2025 total revenues of USD 30.3 million and a net loss of USD 67.1 million, or USD 1.30 per share. For FY 2025, total revenues were USD 170.4 million and net loss was USD 193.9 million, or USD 3.76 per share. R&D expenses were USD 59.6 million in Q4 and USD 228.3 million in FY, while G&A expenses were USD 22.4 million in Q4 and USD 82.9 million in FY. Cash, cash equivalents and marketable securities totaled USD 240.9 million at December 31, 2025, which REGENXBIO said is expected to fund operations into early 2027. On the pipeline, REGENXBIO said it expects pivotal topline data for RGX-202 in Duchenne muscular dystrophy in early Q2 2026 and plans to share additional Phase I/II data at the MDA conference on March 11, 2026, with a pre-BLA meeting request planned for mid-2026. In retinal disease, the company and AbbVie expect Q4 2026 topline pivotal data for surabgene lomparvovec (ABBV-RGX-314) in subretinal wet AMD, and REGENXBIO said first patient dosing in the pivotal Phase IIb/III NAAVIGATE diabetic retinopathy study is expected in Q2 2026, which would trigger a USD 100.0 million milestone payment from AbbVie. In neurodegenerative disease, REGENXBIO said the FDA placed clinical holds on RGX-111 and RGX-121 in January 2026, and issued a complete response letter for the RGX-121 BLA in February 2026; the company said it is working to address the CRL with the goal of resubmitting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: PH02050) on March 05, 2026, and is solely responsible for the information contained therein.
Comments